• Four UK IVF groups are actively commercial trialling the Felix System
• Initial commercial orders received from clients within weeks
• UK represents a large fertility market with over 100,000 fertility treatments annually
• Continued commercial momentum across multiple regions

Memphasys Limited (ASX: MEM) has successfully secured entry into the UK market, one of the world's largest IVF markets. The company has reported that four UK IVF groups are actively commercial trialling the Felix System, with initial commercial orders received within weeks of engagement. These trialling clients include large IVF conglomerates conducting over 10,000 cycles per annum and smaller private clinics. Memphasys' Director of Clinical Partnerships and Growth, A/Prof Hassan Bakos, has been instrumental in these engagements, conducting direct clinic visits and securing commercial agreements. The UK commercial progression is part of Memphasys' broader strategy to build a global network of Felix-adopting clinics, underpinned by a recurring revenue model.

Memphasys expects the momentum to build further over the coming weeks, with additional order conversions anticipated.